What are Sotoracib and Adagrasib?

Sotorasib and Adagrasib (Adagrasib) are new anti-cancer drugs used to treat lung cancer. They are both inhibitors targeting the KRAS G12C mutation, but they have some differences.

Sotoracib is a KRAS G12C mutation inhibitor, mainly used to treat KRAS G12C mutated non-small cell lung cancer (NSCLC). This mutation is common in a variety of cancers, especially in patients with non-small cell lung cancer, so the development of sotoracib provides a new treatment option for lung cancer caused by this specific gene mutation. Its mechanism of action is to specifically interfere with the activity of KRAS G12C mutant and block abnormal signaling pathways in cancer cells, thereby inhibiting the growth and spread of tumors.

And adagrasib is also a KRAS G12C inhibitor, specifically used to treat KRAS G12C mutant lung cancer. It is similar to sotorasiib, blocking the activity of KRAS G12C mutant and interfering with abnormal cell signaling in order to inhibit the development of tumors. Clinical trial results of adagrasib showed that some patients showed encouraging anti-tumor activity after treatment, which provides a new and promising treatment avenue for patients with KRAS G12C mutant lung cancer.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs. Adagrasib is currently only the original drug, and the price is as high as more than 180,000 yuan.